Recent Sentinel Activity

This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.

RSS Feed

URL	Title	Category	Date	Recent Activity
https://sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation	COVID-19 Pregnancy Study Implementation	Methods, Data, & Tools	02/24/2021	COVID-19 Pregnancy Study Implementation Methods, Data, & Tools 02/24/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/follow-time-guselkumab-risankizumab-and-tildrakizumab-users	Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis	Modular Programs	03/30/2021	Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis Modular Programs 03/30/2021
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/ebglyss-lebrikizumab	Assessment of ARIA Sufficiency: Ebglyss (lebrikizumab)	Sufficiency Assessments	04/08/2021	Assessment of ARIA Sufficiency: Ebglyss (lebrikizumab) Sufficiency Assessments 04/08/2021
https://sentinelinitiative.org/methods-data-tools/methods/improving-probabilistic-phenotyping-incident-outcomes-through-enhanced	Improving Probabilistic Phenotyping of Incident Outcomes through Enhanced Ascertainment with Natural Language Processing	Methods, Data, & Tools	05/20/2021	Improving Probabilistic Phenotyping of Incident Outcomes through Enhanced Ascertainment with Natural Language Processing Methods, Data, & Tools 05/20/2021
https://sentinelinitiative.org/methods-data-tools/methods/making-medicaid-data-more-accessible-through-common-data-models-and-fhir	Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs	Methods, Data, & Tools	09/24/2021	Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs Methods, Data, & Tools 09/24/2021
https://sentinelinitiative.org/news-events/publications-presentations/utilization-post-exposure-prophylaxis-prevent-lyme-disease	Utilization of Post-Exposure Prophylaxis to Prevent Lyme Disease in a Large US Healthcare Database	Publications and Presentations	09/29/2021	Utilization of Post-Exposure Prophylaxis to Prevent Lyme Disease in a Large US Healthcare Database Publications and Presentations 09/29/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/n-nitrosodimethylamine-ndma-contaminated-and-non-ndma	N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis	Analyses	02/18/2022	N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis Analyses 02/18/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-n-nitrosodimethylamine-ndma-and-n	Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis	Analyses	03/01/2022	Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis Analyses 03/01/2022
https://sentinelinitiative.org/methods-data-tools/methods/augmenting-date-death-cause-death-ascertainment-sentinel	Augmenting Date of Death & Cause of Death Ascertainment in Sentinel	Methods, Data, & Tools	03/16/2022	Augmenting Date of Death & Cause of Death Ascertainment in Sentinel Methods, Data, & Tools 03/16/2022
https://sentinelinitiative.org/methods-data-tools/methods/approaches-handling-partially-observed-confounder-data-electronic-health	Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes	Methods, Data, & Tools	06/01/2022	Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes Methods, Data, & Tools 06/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bamlanivimab-bamlanivimab-and-etesevimab-and-casirivimab	Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis	Analyses	06/14/2022	Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis Analyses 06/14/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use	Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis	Analyses	06/24/2022	Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis Analyses 06/24/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hospitalization-and-anaphylaxis-following-monoclonal	Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis	Analyses	07/14/2022	Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis Analyses 07/14/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use-0	Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis	Analyses	08/24/2022	Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis Analyses 08/24/2022
https://sentinelinitiative.org/news-events/publications-presentations/characterizing-medication-use-among-pregnancies-covid-19	Characterizing Medication Use Among Pregnancies with COVID-19 in the Sentinel System	Publications and Presentations	08/26/2022	Characterizing Medication Use Among Pregnancies with COVID-19 in the Sentinel System Publications and Presentations 08/26/2022
https://sentinelinitiative.org/news-events/publications-presentations/impact-nitrosamine-contamination-recalls-angiotensin	Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark	Publications and Presentations	08/26/2022	Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark Publications and Presentations 08/26/2022
https://sentinelinitiative.org/news-events/publications-presentations/identification-obesity-and-tobacco-use-claims-compared	Identification of Obesity and Tobacco Use in Claims Compared to Electronic Health Record (EHR) Data	Publications and Presentations	08/28/2022	Identification of Obesity and Tobacco Use in Claims Compared to Electronic Health Record (EHR) Data Publications and Presentations 08/28/2022
https://sentinelinitiative.org/news-events/publications-presentations/describing-prenatal-exposures-and-evaluating-maternal-and	Describing Prenatal Exposures and Evaluating Maternal and Infant Outcomes in Sentinel	Publications and Presentations	09/13/2022	Describing Prenatal Exposures and Evaluating Maternal and Infant Outcomes in Sentinel Publications and Presentations 09/13/2022
https://sentinelinitiative.org/methods-data-tools/methods/onboarding-commercial-electronic-health-record-ehr-data-partners	Onboarding of Commercial Electronic Health Record (EHR) Data Partners	Methods, Data, & Tools	11/01/2022	Onboarding of Commercial Electronic Health Record (EHR) Data Partners Methods, Data, & Tools 11/01/2022
https://sentinelinitiative.org/methods-data-tools/methods/inclusion-semi-structured-and-unstructured-electronic-health-record-ehr	Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment	Methods, Data, & Tools	12/09/2022	Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment Methods, Data, & Tools 12/09/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-patients-and-encounters-trinetx-live-usa	Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis	Analyses	01/12/2023	Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis Analyses 01/12/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-or-linked-infant	Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis	Analyses	03/03/2023	Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Analyses 03/03/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-records-following	Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis	Analyses	03/03/2023	Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Analyses 03/03/2023
https://sentinelinitiative.org/news-events/publications-presentations/valsartan-losartan-and-irbesartan-use-usa-uk-canada-and	Valsartan, Losartan and Irbesartan Use in the USA, UK, Canada and Denmark After the Nitrosamine Recalls: A Descriptive Cohort Study	Publications and Presentations	04/17/2023	Valsartan, Losartan and Irbesartan Use in the USA, UK, Canada and Denmark After the Nitrosamine Recalls: A Descriptive Cohort Study Publications and Presentations 04/17/2023
https://sentinelinitiative.org/methods-data-tools/methods/creating-sentinel-linked-electronic-health-record-ehr-claims-development	Creating a Sentinel Linked Electronic Health Record (EHR)-claims Development Network	Methods, Data, & Tools	04/18/2023	Creating a Sentinel Linked Electronic Health Record (EHR)-claims Development Network Methods, Data, & Tools 04/18/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-trinetx-five	Characterization of Cannabis-Derived Product Users in TriNetX: Five Descriptive Analyses	Analyses	07/19/2023	Characterization of Cannabis-Derived Product Users in TriNetX: Five Descriptive Analyses Analyses 07/19/2023
https://sentinelinitiative.org/news-events/publications-presentations/characterizing-medication-use-patterns-among-pregnant-and	Characterizing Medication Use Patterns Among Pregnant and Non-Pregnant Patients with COVID-19 in the Sentinel System	Publications and Presentations	08/25/2023	Characterizing Medication Use Patterns Among Pregnant and Non-Pregnant Patients with COVID-19 in the Sentinel System Publications and Presentations 08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/high-dose-dexamethasone-covid-19-not-common-large-us	High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network	Publications and Presentations	08/25/2023	High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network Publications and Presentations 08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/expanding-capabilities-unapproved-cannabis-derived-product	Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022	Publications and Presentations	08/27/2023	Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022 Publications and Presentations 08/27/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-guselkumab-risankizumab-tildrakizumab-and	Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis	Analyses	12/07/2023	Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Analyses 12/07/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/medication-use-among-pregnant-individuals-covid-19-0	Medication Use Among Pregnant Individuals With COVID-19: A Descriptive Analysis	Analyses	01/11/2024	Medication Use Among Pregnant Individuals With COVID-19: A Descriptive Analysis Analyses 01/11/2024
https://sentinelinitiative.org/studies/drugs/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-ii-receptor-blockers	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Signal Identification	Studies	03/18/2024	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Signal Identification Studies 03/18/2024
https://sentinelinitiative.org/news-events/publications-presentations/targeted-learning-undersmoothed-lasso-propensity-score-model	Targeted Learning with an Undersmoothed Lasso Propensity Score Model for Large-Scale Covariate Adjustment in Healthcare Database Studies	Publications and Presentations	03/21/2024	Targeted Learning with an Undersmoothed Lasso Propensity Score Model for Large-Scale Covariate Adjustment in Healthcare Database Studies Publications and Presentations 03/21/2024
https://sentinelinitiative.org/studies/drugs/new-onset-cancer	New-Onset Cancer & Duration of Follow-up	Studies	03/22/2024	New-Onset Cancer & Duration of Follow-up Studies 03/22/2024
https://sentinelinitiative.org/news-events/publications-presentations/validity-inpatient-electronic-health-record-based-measures	Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints	Publications and Presentations	04/02/2024	Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints Publications and Presentations 04/02/2024
https://sentinelinitiative.org/news-events/fda-safety-communications-labeling-changes/fda-labeling-change-vedolizumab-interstitial	FDA Labeling Change: Vedolizumab & Interstitial Lung Disease (ILD)	Regulatory Impact	04/18/2024	FDA Labeling Change: Vedolizumab & Interstitial Lung Disease (ILD) Regulatory Impact 04/18/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/concomitant-use-medications-drug-drug-interactions	Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis	Analyses	05/17/2024	Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis Analyses 05/17/2024
https://sentinelinitiative.org/studies/drugs/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-ii-receptor-blockers-0	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Pediatric Drug Utilization	Studies	06/13/2024	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Pediatric Drug Utilization Studies 06/13/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-methotrexate-descriptive-analysis-trinetx	Utilization of Methotrexate: A Descriptive Analysis in TriNetX	Analyses	07/17/2024	Utilization of Methotrexate: A Descriptive Analysis in TriNetX Analyses 07/17/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/prevalence-selected-conditions-among-individuals	Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis	Analyses	07/26/2024	Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis Analyses 07/26/2024